VBI Vaccines Inc/BC
DelistedCIK 764195fmd_099FNMA7QVF4KTQM6J0ZXY5S7BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2024, 34 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 9 |
| Cost of revenue | 4 | 4 | 5 | 5 | 8 | 9 | – | – | – |
| Net interest income | – | – | (0) | (1) | – | – | – | – | – |
| Gross profit | (3) | (3) | (4) | (1) | (6) | (8) | – | – | – |
| Research and development | 14 | 10 | 21 | 38 | 26 | 15 | 20 | 16 | 9 |
| Selling, general and administrative | – | – | – | – | – | – | 38 | 56 | 42 |
| Total operating expenses | 25 | 25 | 38 | 64 | 55 | 45 | 69 | 83 | 89 |
| Operating income | (24) | (25) | (37) | (60) | (52) | (44) | (68) | (82) | (80) |
| Interest expense | 1 | 0 | 3 | 3 | 2 | 3 | 5 | 4 | 6 |
| Interest and investment income | – | – | – | – | – | – | 0 | 1 | 2 |
| Income before taxes | (26) | (25) | (39) | (64) | (55) | (46) | (70) | (113) | (93) |
| Income tax expense | (0) | (2) | (0) | – | – | – | – | – | – |
| Net income from continuing operations | (26) | (23) | (39) | – | – | – | – | – | – |
| Net income | (26) | (23) | (39) | (64) | (55) | (46) | (70) | (113) | (93) |
| Net income to common shareholders | – | – | – | – | – | – | – | (113) | (94) |